AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29119300 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment modalities (including antibiotics, IVIG, psychiatric medications, cognitive behavioral therapy)
Number of subjects: 33
Study 26700848 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic maternal hyperoxygenation (CMH) therapy, ≥ 8 hours daily from enrollment until delivery.
Number of subjects: 9
Study 26700848 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic maternal hyperoxygenation (CMH) therapy, > 9 hours daily (n=6).
Number of subjects: 9
Study 24043665 — intervention group
Group type: EXPERIMENTAL
Intervention: soft study shoes (soft-SS)
Number of subjects: 247
Study 24043665 — intervention group
Group type: COMPARATOR
Intervention: hard study shoes (hard-SS)
Number of subjects: 247
Study 22545816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic care model intervention with geriatric in-home assessment every 6 months and tailored care plan.
Number of subjects: 1200
Study 22545816 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1200
Study 20556802 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide, 40 mg intravenous bolus
Number of subjects: 28
Study 20556802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide, 2 microg/kg intravenous bolus followed by a 0.01 microg/kg/min infusion for 6 hours
Number of subjects: 28
Study 20556802 — intervention group
Group type: COMPARATOR
Intervention: Furosemide plus Nesiritide
Number of subjects: 28
Study 18018468 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal surgery (Group A)
Number of subjects: 0
Study 18018468 — intervention group
Group type: COMPARATOR
Intervention: Supportive periodontal therapy (Group B)
Number of subjects: 0
Study 16361986 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatments for mania (specific interventions not detailed)
Number of subjects: 0
Study 16361986 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11915580 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 2.5 mg/24 h transdermal patches
Number of subjects: 24
Study 11915580 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (DCF) 50 mg per os
Number of subjects: 24
Study 11915580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 24
Study 11915580 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 24
Study 10080605 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR 10 mg every 4 weeks
Number of subjects: 79
Study 10080605 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR 20 mg every 4 weeks
Number of subjects: 79
Study 10080605 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR 30 mg every 4 weeks
Number of subjects: 79
Study 10080605 — intervention group
Group type: COMPARATOR
Intervention: Open-label SC octreotide every 8 hours
Number of subjects: 79
Study 7747843 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal sodium diclofenac 100 mg
Number of subjects: 0
Study 7747843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7747843 — intervention group
Group type: COMPARATOR
Intervention: Both groups (diclofenac and placebo)
Number of subjects: 0
Study 8467273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure (Group E)
Number of subjects: 21
Study 8467273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure and cognitive aversion (Group E/CA)
Number of subjects: 21
Study 8467273 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment alone (Group C)
Number of subjects: 21
Study 2880690 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-28 (SS-28)
Number of subjects: 8
Study 2880690 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin-14 (SS-14)
Number of subjects: 8
Study 31394282 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training (36 sessions, 1 hour each, 3 times weekly for 12 weeks)
Number of subjects: 39
Study 31394282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in daily activity level)
Number of subjects: 39
Study 30153428 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (ABC group, n=222; 7%)
Number of subjects: 3169
Study 30153428 — intervention group
Group type: COMPARATOR
Intervention: Non-ABC group (n=2947; 93%)
Number of subjects: 3169
Study 30153428 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (ABC group)
Number of subjects: 3169
Study 26813524 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD; 1250 kcal/day) for 12 weeks
Number of subjects: 57
Study 26813524 — intervention group
Group type: COMPARATOR
Intervention: Very-low-calorie diet (VLCD; 500 kcal/day) for 5 weeks
Number of subjects: 57
Study 26813524 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD; 500 kcal/day)
Number of subjects: 57
Study 26813524 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet (LCD; 1250 kcal/day)
Number of subjects: 57
Study 24602167 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional restorations (CR)
Number of subjects: 169
Study 24602167 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall technique (HT)
Number of subjects: 169
Study 24602167 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-restorative caries treatment (NRCT)
Number of subjects: 169
Study 24602167 — intervention group
Group type: COMPARATOR
Intervention: Control group (CR)
Number of subjects: 169
Study 23446173 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity practical blood flow restriction (LI-pBFR)
Number of subjects: 12
Study 23446173 — intervention group
Group type: COMPARATOR
Intervention: Control (zero pressure wraps)
Number of subjects: 12
Study 21335372 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C cutoff of 5.9%
Number of subjects: 10038
Study 21335372 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C cutoff of 5.6%
Number of subjects: 10038
Study 21335372 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline A1C ≥5.6%
Number of subjects: 10038
Study 19156568 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 microg as an intravenous bolus) with naloxone (2 mg bolus followed by 1.6 mg/h infusion)
Number of subjects: 11
Study 19156568 — intervention group
Group type: COMPARATOR
Intervention: GHRH (100 microg as an intravenous bolus) without naloxone
Number of subjects: 11
Study 16569097 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SUPPORT intervention
Number of subjects: 0
Study 16569097 — intervention group
Group type: COMPARATOR
Intervention: Existing services condition (Control)
Number of subjects: 0
Study 15273018 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback about performance on a verbal task
Number of subjects: 0
Study 15273018 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback about performance on a verbal task
Number of subjects: 0
Study 15273018 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative feedback (single or aggregated target)
Number of subjects: 0
Study 15273018 — intervention group
Group type: COMPARATOR
Intervention: Objective standard feedback
Number of subjects: 0
Study 11074396 — intervention group
Group type: EXPERIMENTAL
Intervention: ss2-agonist
Number of subjects: 86
Study 11074396 — intervention group
Group type: EXPERIMENTAL
Intervention: ss2-agonist and ICS
Number of subjects: 86
Study 9512845 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.54% hyperbaric lidocaine (48 mg)
Number of subjects: 43
Study 9512845 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% hyperbaric lidocaine (72 mg)
Number of subjects: 43
Study 7836703 — intervention group
Group type: EXPERIMENTAL
Intervention: High prolactin release (delta prolactin > 1000 mu u/ml, n = 11)
Number of subjects: 19
Study 7836703 — intervention group
Group type: COMPARATOR
Intervention: Low prolactin release (delta prolactin < 1000 mu u/ml, n = 8)
Number of subjects: 19
Study 2975199 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dapsone daily for 16 weeks
Number of subjects: 40
Study 2975199 — intervention group
Group type: COMPARATOR
Intervention: 40 mg 13‐cis retinoic acid daily for 16 weeks
Number of subjects: 40
Study 31400333 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe atheroma grade (grade III-V)
Number of subjects: 383
Study 31400333 — intervention group
Group type: COMPARATOR
Intervention: Mild atheroma grade (grade I-II)
Number of subjects: 383
Study 29756523 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education by pharmacists (lifestyle intervention)
Number of subjects: 190
Study 27038277 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic right colectomy (LRC)
Number of subjects: 34
Study 27038277 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic-assisted colonoscopic polypectomy (LACP)
Number of subjects: 34
Study 25204013 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium lactate (360 mg elemental magnesium)
Number of subjects: 98
Study 25204013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 22828734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Number of subjects: 12
Study 22828734 — intervention group
Group type: COMPARATOR
Intervention: Control (iso-energetic and iso-proteinaceous supplement)
Number of subjects: 12
Study 20625131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (200 mg/d)
Number of subjects: 360
Study 20625131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 20625131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (for patients who developed grade 2 or worse HFS in the placebo group)
Number of subjects: 360
Study 20625131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for patients who developed grade 2 or worse HFS in the placebo group)
Number of subjects: 360
Study 18794505 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional relaxation
Number of subjects: 22
Study 18794505 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 16789505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) patients
Number of subjects: 20
Study 12439645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine and caffeine (20/200 mg, three times daily) for 4 weeks
Number of subjects: 0
Study 12439645 — intervention group
Group type: COMPARATOR
Intervention: Hypoenergetic diet (70% of energy expenditure)
Number of subjects: 0
Study 12439645 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated obese subjects)
Number of subjects: 0
Study 9101609 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolality contrast medium (ioxaglic acid - Hexabrix)
Number of subjects: 39
Study 9101609 — intervention group
Group type: COMPARATOR
Intervention: Control group (renal donors)
Number of subjects: 39
Study 9101609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 39
Study 9101609 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diseases of multiple etiologies
Number of subjects: 39
Study 9101609 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate renal function deficit (CrCl 25 to 60 mL/min)
Number of subjects: 39
Study 9101609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild renal function deficit (CrCl >= 60 mL/min)
Number of subjects: 39
Study 2779901 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic regimens in the trial
Number of subjects: 50
Study 2779901 — intervention group
Group type: COMPARATOR
Intervention: Pretrial patients
Number of subjects: 50
Study 2779901 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial patients
Number of subjects: 50
Study 1105628 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 0
Study 1105628 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT treatment
Number of subjects: 0
Study 1105628 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid administration
Number of subjects: 0
Study 31829287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 933
Study 31829287 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (comparator arm)
Number of subjects: 933
Study 27562843 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral dynamic knee-extension exercise
Number of subjects: 0
Study 27562843 — intervention group
Group type: COMPARATOR
Intervention: α-fluoromethylhistidine hydrochloride (α-FMH)
Number of subjects: 0
Study 27562843 — intervention group
Group type: COMPARATOR
Intervention: H1/H2-receptor blockers
Number of subjects: 0
Study 27562843 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 25465711 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (1 ml methylprednisolone acetate)
Number of subjects: 75
Study 25465711 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (1 ml methylprednisolone acetate + 15-day delayed 2 ml saline 0.9 %)
Number of subjects: 75
Study 25465711 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (1 ml methylprednisolone acetate + 15-day delayed 2 ml low molecular weight hyaluronic acid)
Number of subjects: 75
Study 23635091 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 70
Study 23635091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 70
Study 23635091 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 70
Study 23635091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22076090 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral plyometric training
Number of subjects: 49
Study 22076090 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral plyometric training
Number of subjects: 49
Study 22076090 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 19726909 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care nursing based palliative care program (experimental group)
Number of subjects: 46
Study 17378196 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with point-injection
Number of subjects: 60
Study 17378196 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study 15126927 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 70
Study 15126927 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 70
Study 11346005 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CSU‐13B/P anti‐G suit (STD)
Number of subjects: 6
Study 11346005 — intervention group
Group type: EXPERIMENTAL
Intervention: STD suit with COMBAT EDGE (CE)
Number of subjects: 6
Study 11346005 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Technology Anti‐G Suit (ATAGS)
Number of subjects: 6
Study 11346005 — intervention group
Group type: EXPERIMENTAL
Intervention: ATAGS with COMBAT EDGE (CE)
Number of subjects: 6
Study 11346005 — intervention group
Group type: COMPARATOR
Intervention: Seat-back angle effect
Number of subjects: 6
Study 11346005 — intervention group
Group type: COMPARATOR
Intervention: Protective equipment effect
Number of subjects: 6
Study 11346005 — intervention group
Group type: EXPERIMENTAL
Intervention: ATAGS/CE with 13 and 30 degree seat-back angle
Number of subjects: 6
Study 11346005 — intervention group
Group type: EXPERIMENTAL
Intervention: ATAGS/CE with 55 degree seat-back angle
Number of subjects: 6
Study 11346005 — intervention group
Group type: EXPERIMENTAL
Intervention: ATAGS/CE with moderate straining at 55 degrees
Number of subjects: 6
Study 11346005 — intervention group
Group type: EXPERIMENTAL
Intervention: ATAGS/CE with additional straining at 13 and 30 degrees
Number of subjects: 6
Study 9741373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose mask CPAP therapy
Number of subjects: 30
Study 9741373 — intervention group
Group type: COMPARATOR
Intervention: Face mask CPAP therapy
Number of subjects: 30
Study 9741373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose mask CPAP therapy for SAHS/U3P
Number of subjects: 30
Study 9741373 — intervention group
Group type: COMPARATOR
Intervention: Face mask CPAP therapy for SAHS/U3P
Number of subjects: 30
Study 9741373 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term compliance for SAHS patients
Number of subjects: 30
Study 9741373 — intervention group
Group type: COMPARATOR
Intervention: Long-term compliance for SAHS/U3P patients
Number of subjects: 30
Study 7509355 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 0
Study 7509355 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0
Study 7509355 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0
Study 7509355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3127710 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of carbamazepine
Number of subjects: 92
Study 3127710 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of phenytoin
Number of subjects: 92
Study 3127710 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of sodium valproate
Number of subjects: 92
Study 3127710 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized seizures
Number of subjects: 92
Study 3127710 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex or simple partial seizures without secondary generalized attacks
Number of subjects: 92
Study 3127710 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalographic class 4 (abnormal before treatment and unchanged before withdrawal)
Number of subjects: 92
Study 3127710 — intervention group
Group type: COMPARATOR
Intervention: Adults
Number of subjects: 92
Study 3127710 — intervention group
Group type: COMPARATOR
Intervention: Children
Number of subjects: 92
Study 321502 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol aerosol
Number of subjects: 0
Study 321502 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 0
Study 321502 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosols
Number of subjects: 0
Study 30406289 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) for urinary symptoms (nocturia, incontinence, frequency, dysuria, urgency)
Number of subjects: 160
Study 30406289 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) for gastrointestinal (GI) symptoms (obstruction, diarrhea, vomiting, nausea, bloating, hemorrhage, incontinence)
Number of subjects: 160
Study 30406289 — intervention group
Group type: COMPARATOR
Intervention: Physician-reported outcomes for urinary and GI symptoms
Number of subjects: 160
Study 29029193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact FGF23 in girls
Number of subjects: 721
Study 29029193 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal FGF23 in boys and girls
Number of subjects: 721
Study 29029193 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron concentration
Number of subjects: 721
Study 25793219 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 50
Study 25793219 — intervention group
Group type: COMPARATOR
Intervention: ProSeal LMA
Number of subjects: 50
Study 25793219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 23419284 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine plus best supportive care (BSC)
Number of subjects: 370
Study 23419284 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 370
Study 23419284 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine plus BSC
Number of subjects: 370
Study 22483428 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-incision THA
Number of subjects: 20
Study 22483428 — intervention group
Group type: COMPARATOR
Intervention: Modified Watson-Jones THA
Number of subjects: 20
Study 20437725 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Clearfil SE Bond)
Number of subjects: 0
Study 20437725 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide liner (Dycal)
Number of subjects: 0
Study 17972380 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (betaB)
Number of subjects: 0
Study 17972380 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 0
Study 17972380 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-renin system blockers (ARSB)
Number of subjects: 0
Study 17972380 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACEI)
Number of subjects: 0
Study 17972380 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARB)
Number of subjects: 0
Study 16376756 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma triglyceride levels
Number of subjects: 424
Study 11943522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine, propofol, and fentanyl
Number of subjects: 76
Study 11943522 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane, nitrous oxide, and fentanyl
Number of subjects: 76
Study 9797520 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 40
Study 9797520 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 40
Study 8562538 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% aldose reductase inhibitor (CT-112)
Number of subjects: 13
Study 8562538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2762751 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized stress model
Number of subjects: 19
Study 2762751 — intervention group
Group type: COMPARATOR
Intervention: Non-stressed conditions
Number of subjects: 19
Study 327814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (prophylactic administration)
Number of subjects: 0
Study 327814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 31431411 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4-HD (high-dose quadrivalent influenza vaccine)
Number of subjects: 2670
Study 28532660 — intervention group
Group type: EXPERIMENTAL
Intervention: micro-dose recombinant HCG
Number of subjects: 100
Study 28532660 — intervention group
Group type: COMPARATOR
Intervention: recombinant LH
Number of subjects: 100
Study 25294531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy (n = 45)
Number of subjects: 90